Phaseline

Companies › OX2 Therapeutics

OX2 Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 7 registered trials: 4 Phase 1, 1 Phase 4, 1 Phase 3, 1 Phase 2; Genitourinary, Oncology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Imiquimod
Toll-like receptor 7 agonist
TLR7Phase 1Diffuse Midline Glioma, H3 K27M-Mutant; HSIL, High-Grade Squamous Intraepithelial Lesions; Basal Cell Carcinoma; Cervical Carcinoma …Jan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06356012ImiquimodPhase 4HSIL, High-Grade Squamous Intraepithelial LesionsGenitourinaryDec 2026
NCT06305910ImiquimodPhase 1Diffuse Midline Glioma, H3 K27M-MutantOncologyJan 2027
NCT06305910ImiquimodPhase 1Diffuse Midline Glioma, H3 K27M-MutantOncologyJan 2027
NCT07210775ImiquimodPhase 1Oral DysplasiaOncologyOct 2027
NCT06686043ImiquimodPhase 2Cervical CarcinomaOncologyAug 2028
NCT07251413ImiquimodPhase 1Cutaneous Basal Cell CarcinomaOncologyDec 2028
NCT05212246ImiquimodPhase 3Basal Cell CarcinomaOncologyOct 2032

Targets

TLR7 (1)

Companies with the same targets

Merck KGaA Eikon Therapeutics United Immunity Beeline Medicines Primmune Therapeutics HighField Biopharmaceuticals Ascendis Pharma Oncology Division Bolt Biotherapeutics Inimmune

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.